Protective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancers (scientific article published on 04 March 2019)

A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas

Q27853017

The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data

Q28266682

Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal

Q28288215

Autophagy inhibition overcomes multiple mechanisms of resistance to BRAF inhibition in brain tumors

Q28468571

AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1

Q28506431

Dissection of the autophagosome maturation process by a novel reporter protein, tandem fluorescent-tagged LC3

Q29614176

Phosphorylation of ULK1 (hATG1) by AMP-activated protein kinase connects energy sensing to mitophagy

Q29615616

Drug combination studies and their synergy quantification using the Chou-Talalay method

Q29617422

Pancreatic cancer

Q29622871

An Atg4B mutant hampers the lipidation of LC3 paralogues and causes defects in autophagosome closure

Q30484302

Comparative benefits of Nab-paclitaxel over gemcitabine or polysorbate-based docetaxel in experimental pancreatic cancer

Q33621256

Sorting cells for basal and induced autophagic flux by quantitative ratiometric flow cytometry

Q34373145

Uncoupling cancer mutations reveals critical timing of p53 loss in sarcomagenesis

Q35177312

Small Molecule Inhibition of the Autophagy Kinase ULK1 and Identification of ULK1 Substrates.

Q35676481

A central role for RAF→MEK→ERK signaling in the genesis of pancreatic ductal adenocarcinoma.

Q36182645

Macroautophagy is dispensable for growth of KRAS mutant tumors and chloroquine efficacy

Q36459468

Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor

Q36929804

Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism

Q37113394

Oncogenic B-RAF negatively regulates the tumor suppressor LKB1 to promote melanoma cell proliferation

Q37274568

Hydroxychloroquine: from malaria to autoimmunity

Q37827403

Chloroquine-induced glioma cells death is associated with mitochondrial membrane potential loss, but not oxidative stress.

Q38818900

Autophagy inhibition improves chemosensitivity in BRAF(V600E) brain tumors

Q38995480

Targeting ER stress-induced autophagy overcomes BRAF inhibitor resistance in melanoma.

Q39020884

Cancer Statistics, 2017.

Q39038674

p53 status determines the role of autophagy in pancreatic tumour development

Q39048945

Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors

Q39161270

The treatment of malaria

Q39590029

GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition

Q39606314

Combenefit: an interactive platform for the analysis and visualization of drug combinations.

Q39788218

Pancreatic stellate cells support tumour metabolism through autophagic alanine secretion.

Q41432721

Targeting autophagy in cancer

Q41912265

Mitochondrial membrane permeabilization is a critical step of lysosome-initiated apoptosis induced by hydroxychloroquine.

Q41915692

Potent, Selective, and Orally Bioavailable Inhibitors of VPS34 Provide Chemical Tools to Modulate Autophagy in Vivo

Q43083919

Autophagy sustains pancreatic cancer growth through both cell autonomous and non-autonomous mechanisms

Q47742163

Autophagy maintains tumour growth through circulating arginine

Q59066319

Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)

Q22676705

The AMPK signalling pathway coordinates cell growth, autophagy and metabolism

Q24616273

Novel Carboxamide-Based Allosteric MEK Inhibitors: Discovery and Optimization Efforts toward XL518 (GDC-0973)

Q27684146

A highly potent and selective Vps34 inhibitor alters vesicle trafficking and autophagy

Q27695718

P2507

corrigendum / erratum

Publisher Correction: Protective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancers

Q92659388

P433

issue

P921

main subject

autophagy

Q288322

P304

page(s)

620-627

P577

publication date

2019-03-04

P1433

published in

Nature Medicine

Q1633234

P1476

title

Protective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancers

P478

volume

Reverse relations

cites work (P2860)

Q92642778	Adaptive Responses as Mechanisms of Resistance to BRAF Inhibitors in Melanoma
Q90474285	Analysis of lncRNA-mRNA networks after MEK1/2 inhibition based on WGCNA in pancreatic ductal adenocarcinoma
Q92476256	Applications of patient-derived tumor xenograft models and tumor organoids
Q90382919	Autophagy Function and Dysfunction: Potential Drugs as Anti-Cancer Therapy
Q99418507	Autophagy as a therapeutic target in pancreatic cancer
Q91973791	Autophagy in cancer: moving from understanding mechanism to improving therapy responses in patients
Q92489107	Autophagy inhibitor combination strategies for pancreatic cancer
Q92532340	Autophagy-dependent ferroptosis drives tumor-associated macrophage polarization via release and uptake of oncogenic KRAS protein
Q95841647	Autophagy: When to strike?
Q92637541	Blocking autophagy to starve pancreatic cancer
Q99550782	Chloroquine sensitizes GNAQ/11-mutated melanoma to MEK1/2 inhibition
Q89983214	Clarithromycin inhibits autophagy in colorectal cancer by regulating the hERG1 potassium channel interaction with PI3K
Q92431789	Colorectal cancer cells respond differentially to autophagy inhibition in vivo
Q64069077	Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer
Q90485648	Comparison of autophagy inducibility in various tyrosine kinase inhibitors and their enhanced cytotoxicity via inhibition of autophagy in cancer cells in combined treatment with azithromycin
Q89716176	Comprehensive Detection of Single Amino Acid Variants and Evaluation of Their Deleterious Potential in a PANC-1 Cell Line
Q90591246	Copper is an essential regulator of the autophagic kinases ULK1/2 to drive lung adenocarcinoma
Q91751487	Differential expression of MAGEA6 toggles autophagy to promote pancreatic cancer progression
Q92821345	Dual Targeting of Autophagy and MEK in KRAS Mutant Cancer
Q92528442	EMT and Stemness-Key Players in Pancreatic Cancer Stem Cells
Q96348252	Eating self for not be eaten: Pancreatic cancer suppresses self-immunogenicity by autophagy-mediated MHC-I degradation
Q90084114	Effect of early-stage autophagy inhibition in BRAFV600E autophagy-dependent brain tumor cells
Q92767322	Eliminating protective autophagy in KRAS-mutant cancers
Q96138039	Elimination of dormant, autophagic ovarian cancer cells and xenografts through enhanced sensitivity to anaplastic lymphoma kinase inhibition
Q91199443	From state-of-the-art treatments to novel therapies for advanced-stage pancreatic cancer
Q97529017	Hormonal Regulation of Autophagy in Thyroid PCCL3 Cells and the Thyroids of Male Mice
Q95270414	Identifying Drug Targets in Pancreatic Ductal Adenocarcinoma Through Machine Learning, Analyzing Biomolecular Networks, and Structural Modeling
Q90207146	KRAS-Driven Metabolic Rewiring Reveals Novel Actionable Targets in Cancer
Q92058815	LATS1 but not LATS2 represses autophagy by a kinase-independent scaffold function
Q89638571	Label-free whole-colony imaging and metabolic analysis of metastatic pancreatic cancer by an autoregulating flexible optical system
Q83547406	Long noncoding RNA ITGB2-AS1 promotes growth and metastasis through miR-4319/RAF1 axis in pancreatic ductal adenocarcinoma
Q89980729	Metabolism of pancreatic cancer: paving the way to better anticancer strategies
Q90706520	New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness
Q100504067	Non-genetic mechanisms of therapeutic resistance in cancer
Q90428733	Novel therapeutic approaches for pancreatic cancer by combined targeting of RAF→MEK→ERK signaling and autophagy survival response
Q90321317	Palliative chemotherapy in pancreatic cancer-treatment sequences
Q90710469	Pancreatic Adenocarcinoma: Unconventional Approaches for an Unconventional Disease
Q93163810	Pancreatic cancer hidden in plain sight
Q100762044	Post-translational modification of KRAS: potential targets for cancer therapy
Q97526399	Proteomics reveals a therapeutic vulnerability via the combined blockade of APE1 and autophagy in lung cancer A549 cells
Q90629924	RAS, wanted dead or alive: Advances in targeting RAS mutant cancers
Q96302844	RAS-targeted therapies: is the undruggable drugged?
Q90086342	Recent insights into the biology of pancreatic cancer
Q98513798	Regulation and modulation of antitumor immunity in pancreatic cancer
Q92187422	Regulation of Apoptosis by Autophagy to Enhance Cancer Therapy
Q89475388	Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer
Q92500806	Role of tumor and host autophagy in cancer metabolism
Q90065524	Starvation-induced autophagy via calcium-dependent TFEB dephosphorylation is suppressed by Shigyakusan
Q92242813	Stem Cell Plasticity and Dormancy in the Development of Cancer Therapy Resistance
Q99413719	Structural basis for the action of the drug trametinib at KSR-bound MEK
Q92663940	Targeting Aberrant RAS/RAF/MEK/ERK Signaling for Cancer Therapy
Q92048149	Targeting the Tumor Microenvironment: An Unexplored Strategy for Mutant KRAS Tumors
Q92440979	The Role of Autophagy in Pancreatic Cancer-Recent Advances
Q93062047	Usefulness of rapid on-site evaluation specimens from endoscopic ultrasound-guided fine-needle aspiration for cancer gene panel testing: A retrospective study

P356	DOI	10.1038/S41591-019-0367-9
P932	PMC publication ID	6452642
P698	PubMed publication ID	30833748